Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: evidence from a systematic review
Article
Article Title | Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: evidence from a systematic review |
---|---|
ERA Journal ID | 39745 |
Article Category | Article |
Authors | Mahumud, Rashidul Alam (Author), Alam, Khorshed (Author), Keramat, Syed Afroz (Author), Ormsby, Gail M. (Author), Dunn, Jeff (Author) and Gow, Jeff (Author) |
Journal Title | PLoS One |
Journal Citation | 15 (6), pp. 1-15 |
Article Number | e0233499 |
Number of Pages | 15 |
Year | 2020 |
Publisher | Public Library of Science (PLoS) |
Place of Publication | United States |
ISSN | 1932-6203 |
Digital Object Identifier (DOI) | https://doi.org/10.1371/journal.pone.0233499 |
Web Address (URL) | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0233499 |
Abstract | Introduction: The World Health Organization (WHO) recommends that human papillomavirus (HPV) vaccination programs are established to be cost-effective before implementation. WHO recommends HPV vaccination for girls aged 9–13 years to tackle the high burden of cervical cancer. This review examined the existing evidence on the cost-effectiveness of the 9-valent HPV vaccine within a global context. Methods: The literature search covering a period of January 2000 to 31 July 2019 was conducted in PubMed and Scopus bibliographic databases. A combined checklist (i.e., WHO, Drummond and CHEERS) was used to examine the quality of eligible studies. A total of 12 studies were eligible for this review and most of them were conducted in developed countries. Results: Despite some heterogeneity in approaches to measure cost-effectiveness, ten studies concluded that 9vHPV vaccination was cost-effective and two did not. The addition of adolescent boys into immunisation programs was cost effective when vaccine price and coverage was comparatively low. When vaccination coverage for females was more than 75%, gender neutral HPV vaccination was less cost-effective than vaccination targeting only girls aged 9–18 years. Multi cohort immunization approach was found cost-effective in the age range of 9–14 years. However, the upper age limit at which vaccination was found not cost-effective requires further evaluation. This review identified duration of vaccine protection, time horizon, vaccine price, coverage, healthcare costs, efficacy and discounting rates as the most dominating parameters in determining cost-effectiveness. Conclusions: These findings have implications in extending HPV immunization programs whether switching to the 9-valent vaccine or the inclusion of adolescent boys’ vaccination or extending the age of vaccination. Further, this review also supports extending vaccination programs to low-resource settings where vaccine prices are competitive, donor funding is available, burden of cervical cancer is high and screening options are limited. |
Keywords | cervical cancer; cost-effective analysis; HPV vaccination; immunisation program; systematic literature review |
ANZSRC Field of Research 2020 | 429999. Other health sciences not elsewhere classified |
380108. Health economics | |
320213. Medical genetics (excl. cancer genetics) | |
Byline Affiliations | School of Commerce |
School of Health and Wellbeing | |
Centre for Health Research | |
Institution of Origin | University of Southern Queensland |
https://research.usq.edu.au/item/q5y09/cost-effectiveness-evaluations-of-the-9-valent-human-papillomavirus-hpv-vaccine-evidence-from-a-systematic-review
Download files
241
total views139
total downloads1
views this month0
downloads this month